Estrogen receptor β ligands: Recent advances and biomedical applications

Medicinal Research Reviews

Volumn 31, Issue 3, 2011, Pages 364-442

  Minutolo, Filippo ^a   Macchia, Marco ^a   Katzenellenbogen, Benita S ^b   Katzenellenbogen, John A ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Agonist; Antagonist; Binding; Estrogen receptor ; Estrogens; Ligand; Pharmacophore

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 3BETA ANDROSTANEDIOL; ANDROSTANEDIOL; ANDROSTENEDIOL; ANDROSTENEDIOL DERIVATIVE; APIGENIN; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BIOCHANIN A; COUMESTROL; DAIDZEIN; DIARYLPROPIONITRILE; ESTRADIOL DERIVATIVE; ESTRIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GINSENOSIDE RB 1; IMIDAZOLE DERIVATIVE; INDENE DERIVATIVE; INDOLE DERIVATIVE; KAEMPFEROL; LIQUIRITIGENIN; NARINGENIN; PHTHALIMIDE DERIVATIVE; PRINABEREL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOMEDICINE; BREAST; BREAST CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COLON DISEASE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOMETRIOSIS; FERTILITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IC 50; METABOLIC REGULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; RNA TRANSLATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOMEDICAL RESEARCH; ESTROGEN RECEPTOR BETA; ESTROGENS; HUMANS; LIGANDS;

EID: 79953321479     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20186     Document Type: Article

References (233)

1. Harris HA. The unexpected science of estrogen receptor-beta selective agonists: A new class of anti-inflammatory agents? Nucl Recept Signal 2006;4:e012.
2. Harris HA. Estrogen receptor-beta: Recent lessons from in vivo studies. Mol Endocrinol 2007;21:1-13.
3. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005;67:285-308.
4. Pettersson K, Gustafsson J-Å. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001;63:165-192.
5. Zhao C, Dahlman-Wright K, Gustafsson J-Å. Estrogen receptor beta: An overview and update. Nucl Recept Signal 2008;6:e003.
6. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
7. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson J-Å, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758.
8. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000;24:145-155.
9. Antal MC, Krust A, Chambon P, Mark M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci USA 2008;105:2433-2438.
10. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson J-Å. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 2004;101:9375-9380.
11. Fox EM, Davis RJ, Shupnik MA. ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 2008;73:1039-1351.
12. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson J-Å, Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol 2003;17:203-208.
13. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 1999;140:800-804.
14. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006;147:4831-4842.
15. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-428.
16. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson J-Å. Estrogen receptor beta inhibits 17 beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566-1571.
17. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson J-Å. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008;27:1019-1032.
18. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006;66:7334-7340.
19. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen receptors alpha and beta as determinants of gene expression: Influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008;22:1032-1043.
20. Harris HA. Preclinical characterization of selective estrogen receptor beta agonists: New insights into their therapeutic potential. Ernst Schering Found Symp Proc 2006;149-161.
21. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009;69:5415-5423.
22. Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 2008;73:870-873.
23. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008;70:165-190.
24. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 2007;265-266:138-142.
25. Filardo EJ, Thomas P. GPR30: A seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005;16:362-367.
26. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: A key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006;103:13162-13167.
27. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O. Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 2008;110:507-520.
28. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006;116:561-570.
29. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-131.
30. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-1644.
31. Bryant HU. Selective estrogen receptor modulators. Rev Endocr Metab Disord 2002;3:231-241.
32. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-1111.
33. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 2003;46:883-908.
34. Veeneman GH. Non-steroidal subtype selective estrogens. Curr Med Chem 2005;12:1077-1136.
35. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210.
36. Henke BR, Heyer D. Recent advances in estrogen receptor modulators. Curr Opin Drug Disc Dev 2005;8:437-448.
37. Hermkens PHH, Kamp S, Lusher S, Veeneman G. Non-steroidal steroid receptor modulators. IDrugs 2006;9:488-494.
38. Redden PR. Selective oestrogen receptor modulators, pure antiestrogens and related oestrogen receptor ligands. Expert Opin Ther Patents 2004;14:337-353.
39. Ullrich JW, Miller CP. Estrogen receptor modulator review. Expert Opin Ther Patents 2006;16:559-572.
40. Blizzard TA. Selective estrogen receptor modulator medicinal chemistry at Merck. A review. Curr Top Med Chem 2008;8:792-812.
41. Agatonovic-Kustrin S, Turner JV. Molecular structural characteristics of estrogen receptor modulators as determinants of estrogen receptor selectivity. Mini-Rev Med Chem 2008;8:943-951.
42. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-Å. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252-4263.
43. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor β potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001;44:4230-4251.
44. Weiser MJ, Wu TJ, Handa RJ. Estrogen receptor-β agonist diarylpropionitrile: Biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 2009;150:1817-1825.
45. Sun J, Baudry J, Katzenellenbogen JA, Katzenellenbogen BS. Molecular basis for the subtype discrimination of the estrogen receptor-β-selective ligand, diarylpropionitrile. Mol Endocrinol 2003;17:247-258.
46. Harris HA, Albert LM, Leathurby YL, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC, Jr. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 2003;144:4241-4249.
47. Manas ES, Unwalla RJ, Xu ZB, Malamas MS, Miller CP, Harris HA, Hsiao C, Akopian T, Hum W-T, Malakian K, Wolfrom S, Bapat A, Bhat RA, Stahl ML, Somers WS, Alvarez JC. Structure-based design of estrogen receptor-β selective ligands. J Am Chem Soc 2004;126:15106-15119.
48. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC Jr, Harris HA. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J Med Chem 2004;47:5021-5040.
49. Henke BR, Consler TG, Go N, Hale RL, Hohman DR, Jones SA, Lu AT, Moore LB, Moore JT, Orband-Miller LA, Robinett RG, Shearin J, Spearing PK, Stewart EL, Turnbull PS, Weaver SL, Williams SP, Wisely GB, Lambert MH. A new series of estrogen receptor modulators that display selectivity for estrogen receptor β. J Med Chem 2002;45:5492-5505.
50. Veeneman GH, Loozen HJ, Mestres J, De Zwart EW. (Akzo Nobel NV) 10-Aryl-11-Hbenzo[b]fluorene derivatives and analogs for medicinal use. WO0216316 [Chem Abstr 2002;136:216545].
51. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5, 11-Dialkyl-5, 6, 11, 12-tetrahydrochrysenes. J Med Chem 1999;42:2456-2468.
52. Shiau AK, Barstad D, Radek J, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL. Structural characterization of subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002;9:359-364.
53. Kuiper GGJM, Shughrue PJ, Merchenthaler I, Gustafsson J-Å. The estrogen receptor β subtype: A novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrin 1998;19:253-286.
54. Mishra RG, Stanczyk FZ, Burry KA, Oparil S, Katzenellenbogen BS, Nealen ML, Katzenellenbogen JA, Hermsmeyer RK. Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity. Am J Physiol Heart Circ Physiol 2006;290:H295-H303.
55. Petterson H, Holmberg L, Axelson M, Norlin M. CYP7B1-mediated metabolism of dehydroepiandrosterone and 5α-androstane-3β, 17β-diol-potential role(s) for estrogen signaling. FEBS Journal 2008;275:1778-1789.
56. Gibb W, Hagerman DD. The specificity of the 3β-hydroxysteroid dehydrogenase activity of bovine ovaries toward dehydroepiandrosterone and pregnenolone: Evidence for multiple enzymes. Steroids 1976;28:31-41.
57. Blizzard TA, Gude C, Morgan II JD, Chan W, Birzin ET, Mojena M, Tudela C, Chen F, Knecht K, Su Q, Kraker B, Mosley RT, Holmes MA, Sharma N, Fitzgerald PMD, Rohrer SP, Hammond ML. Androstenediol analogs as ER-β-selective SERMs. Bioorg Med Chem Lett 2006;16:834-838.
58. Gellman SH. On the role of methionine residues in the sequence-independent recognition of nonpolar protein surfaces. Biochemistry 1991;30:6633-6636.
59. Blizzard TA, Gude C, Chan W, Birzin ET, Mojena M, Tudela C, Chen F, Knecht K, Su Q, Kraker B, Holmes MA, Rohrer SP, Hammond ML. Bridged androstenediol analogs as ER-β-selective SERMs. Bioorg Med Chem Lett 2007;17:2944-2948.
60. Blizzard TA, Gude C, Morgan II JD, Chan W, Birzin ET, Mojena M, Tudela C, Chen F, Knecht K, Su Q, Kraker B, Mosley RT, Holmes MA, Rohrer SP, Hammond ML. Androstene-3, 5-dienes as ER-β-selective SERMs. Bioorg Med Chem Lett 2007;17:6295-6298.
61. Bartlett PA, Marlowe CK. Evaluation of intrinsic binding energy from a hydrogen bonding group in an enzyme inhibitor. Science 1987;235:569-571.
62. Grobelny D, Goli UB, Galardy RE. Binding energetics of phosphorus-containing inhibitors of thermolysin. Biochemistry 1989;28:4948-4951.
63. Peters O, Hillisch A, Thieme I, Elger W, Hegele-Hartung C, Kollenkirchen U, Fritzemeier K-H, Patchev V. (Schering AG) Preparation of 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens. WO 2001077139 [Chem Abstr 2001;135:213936].
64. Mueller G, Kollenkirchen U, Kosemund D, Fritzemeier K-H. (Jenapharm G.m.b.H. & Co.) Preparation of 19-nor-17α-pregna-1, 3, 5(10)-trien-17β-ols containing a 21, 16α-lactone ring with a preference for the estrogen alpha receptor. WO 2002026763 [Chem Abstr 2002;136:279608].
65. Hillisch A, Peters O, Kosemund D, Müller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH. Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol 2004;18:1599-1609.
66. Toschi L, Hilbig J, Wintermantel T, Engelhaupt A, Walter A, Fritzemeier KH, Hillisch A. Protein structure-based prediction of animal model suitability for pharmacodynamic studies. Chem Med Chem 2006;1:1237-1248.
67. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect. Clin Cancer Res 2005;11:315-322.
68. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin. Steroids 2008;73:59-68.
69. Asim M, El-Salfiti M, Qian Y, Choueiri C, Salari S, Cheng J, Shadnia H, Bal M, Pratt MAC, Carlson KE, Katzenellenbogen JA, Wright JS, Durst T. Deconstructing estradiol: Removal of B-ring generates compounds which are potent and subtype-selective estrogen receptor agonists. Bioorg Med Chem Lett 2009;19:1250-1253.
70. Papapetropoulos A. A ginseng-derived oestrogen receptor β (ERβ) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. Br J Pharmacol 2007;152:172-174.
71. Cho J, Park W, Lee S, Ahn W, Lee Y. Ginsenoside-Rb1 from Panax ginseng C.A. Meyer activates estrogen receptor-α and -β, independent of ligand binding. J Clin Endocrinol Metab 2004;89:3510-3515.
72. Suzuki KM, Isohama Y, Maruyama H, Yamada Y, Narita Y, Ohta S, Araki Y, Miyata T, Mishima S. Estrogenic activities of fatty acids and a sterol isolated from royal jelly. Evid-based Complement Altern Med 2008;5:295-302.
73. Mersereau JE, Levy N, Staub RE, Baggett S, Zogovic T, Chow S, Ricke WA, Tagliaferri M, Cohen I, Bjeldanes LF, Leitman DC. Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist. Mol Cell Endocrinol 2008;283:49-57. See also, erratum in Mol Cell Endocrinol 2008;295:121.
74. Mallavadhani UV, Narasimhan K, Sudhakar AVS, Mahapatra A, Li W, van Breemen RB. Three new pentacyclic triterpenes and some flavonoids from the fruits of an Indian ayurvedic plant Dendrophthoe falcata and their estrogen receptor binding activity. Chem Pharm Bull 2006;54:740-744.
75. Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, Nicolas JC, Cavaillès V, Balaguer P. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol 2006;71:1459-1469.
76. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE. S-Equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-1079.
77. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004;12:1559-1567.
78. Heemstra JM, Kerrigan SA, Doerge DR, Helferich WG, Boulanger WA. Total synthesis of (S)-equol. Org Lett 2006;8:5441-5443. Erratum in: Org Lett 2007;9:379.
79. Suksamrarn A, Ponglikitmongkol M, Wongkrajang K, Chindaduang A, Kittidanairak S, Jankam A, Yingyongnarongkul B, Kittipanumat N, Chokchaisiri R, Khetkam P, Piyachaturawat P. Diarylheptanoids, new phytoestrogens from the rhizomes of Curcuma comosa: Isolation, chemical modification and estrogenic activity evaluation. Bioorg Med Chem 2008;16:6891-6902.
80. De Angelis M, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Indazole estrogens: Highly selective ligands for the estrogen receptor β. J Med Chem 2005;48:1132-1144.
81. Fink BE, Mortensen DS, Stauffer SR, Aron ZD, Katzenellenbogen JA. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol 1999;6:205-219.
82. Schopfer U, Schoeffter P, Bischoff SF, Nozulak J, Feuerbach D, Floersheim P. Toward selective ERβ agonists for central nervous system disorders: Synthesis and characterization of aryl benzthiophenes. J Med Chem 2002;45:1399-1401.
83. Collini MD, Kaufman DH, Manas ES, Harris HA, Henderson RA, Xu ZB, Unwalla RJ, Miller CP. 7-substituted 2-phenyl-benzofurans as ERβ selective ligands. Bioorg Med Chem Lett 2004;14:4925-4929.
84. McDevitt RE, Malamas MS, Manas ES, Unwalla RJ, Xu ZB, Millere CP, Harris HA. Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett 2005;15:3137-3142.
85. Clegg NJ, Paruthiyil S, Leitman DC, Scanlan TS. Differential response of estrogen receptor subtypes to 1, 3-diarylindene and 2, 3-diarylindene ligands. J Med Chem 2005;48:5989-6003.
86. Jernstedt H, Krüger L, Rhönnstad P, Nöteberg D. Preparation of 2-phenyl indene derivatives as estrogen receptor ligands. (KaroBio AB) WO 2008043567 [Chem Abstr 2008;148:471704].
87. Blizzard TA, Morgan II JD, Mosley RT, Birzin ET, Frisch K, Rohrer SP, Hammond ML. 2-phenylspiroindenes: A novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett 2003;13:479-483.
88. Ullrich JW, Unwalla RJ, Singhaus RR, Jr, Harris HA, Mewshaw RE. Estrogen receptor β ligands: Design and synthesis of new 2-phenyl-isoindole-1, 3-diones. Bioorg Med Chem Lett 2007;17:118-122.
89. Chesworth R, Wessel MD, Heyden L, Mangano FM, Zawistoski MP, Gegnas L, Galluzzo D, Lefker B, Cameron KO, Tickner J, Lu B, Castleberry TA, Petersen DN, Brault A, Perry P, Ng O, Owen TA, Pan L, Ke H-Z, Brown TA, Thompson DD, DaSilva-Jardine P. Estrogen receptor β selective ligands: Discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett 2005;15:5562-5566.
90. Mewshaw RE, Edsall RJ, Jr, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Jr, Harris HA. ERβ ligands 3 exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity. J Med Chem 2005;48:3953-3979.
91. Fang J, Akwabi-Ameyaw A, Britton JE, Katamreddy SR, Navas III F, Miller AB, Williams SP, Gray DW, Orband-Miller LA, Shearin J, Heyer D. Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands. Bioorg Med Chem Lett 2008;18:5075-5077.
92. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR, Triantafillou JA, Wolfe SG, Baer PG. 3-[4-(1, 2-Diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994;37:1550-1552.
93. Wittmann BM, Sherk A, McDonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 2007;67:9549-9560.
94. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 2005;18:413-424.
95. Vu AT, Cohn ST, Manas ES, Harris HA, Mewshaw RE. ERβ ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett 2005;15:4520-4525.
96. Wallace OB, Lauwers KS, Jones SA, Dodge JA. Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett 2003;13:1907-1910.
97. Chesworth R, Zawistoski MP, Lefker BA, Cameron KO, Day RF, Mangano FM, Rosati RL, Colella S, Petersen DN, Brault A, Lu B, Pan LC, Perry P, Ng O, Castleberry TA, Owen TA, Brown TA, Thompson DD, DaSilva-Jardine P. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg Med Chem Lett 2004;14:2729-2733.
98. Kumpulainen H, Mähönen N, Laitinen M-L, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. J Med Chem 2006;49:1207-1211.
99. Minutolo F, Bertini S, Papi C, Carlson KE, Katzenellenbogen JA, Macchia M. Salicylaldoxime moiety as a phenolic "A-ring" substitute in estrogen receptor ligands. J Med Chem 2001;44:4288-4291.
100. Minutolo F, Antonello M, Bertini S, Rapposelli S, Rossello A, Sheng S, Carlson KE, Katzenellenbogen JA, Macchia M. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-substituted 3, 4-diarylsalicylaldoximes on estrogen receptors alpha and beta. Bioorg Med Chem 2003;11:1247-1257.
101. Minutolo F, Antonello M, Bertini S, Ortore G, Placanica G, Rapposelli S, Sheng S, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M. Novel estrogen receptor ligands based on an anthranylaldoxime structure: Role of the phenol-type pseudocycle in the binding process. J Med Chem 2003;46:4032-4042.
102. Tuccinardi T, Bertini S, Martinelli A, Minutolo F, Ortore G, Placanica G, Prota G, Rapposelli S, Carlson KE, Katzenellenbogen JA, Macchia M. Synthesis of anthranylaldoxime derivatives as estrogen receptor ligands and computational prediction of binding modes. J Med Chem 2006;49:5001-5012.
103. Minutolo F, Bellini R, Bertini S, Carboni I, Lapucci A, Pistolesi L, Prota G, Rapposelli S, Solati F, Tuccinardi T, Martinelli A, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M. Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor β. J Med Chem 2008;51:1344-1351.
104. Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA, Macchia M. Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor β. J Med Chem 2009;52:858-867.
105. Edsall RJ, Jr, Harris HA, Manas ES, Mewshaw RE. ERβ ligands. Part 1: The discovery of ERβ selective ligands which embrace the 4-hydroxy-biphenyl template. Bioorg Med Chem 2003;11:3457-3474.
106. Yang C, Edsall R, Jr, Harris HA, Zhang X, Manas ES, Mewshaw RE. ERβ ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg Med Chem 2004;12:2553-2570.
107. Mewshaw RE, Bowen SM, Harris HA, Xu ZB, Manas ES, Cohn ST. ERβ ligands. Part 2: Synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives. Bioorg Med Chem Lett 2007;17:902-906.
108. Richardson TI, Norman BH, Lugar CW, Jones SA, Wang Y, Durbin JD, Krishnan V, Dodge JA. Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 2: Structure-activity relationship studies on the benzopyran scaffold. Bioorg Med Chem Lett 2007;17:3570-3574.
109. Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA, Chen K, Wang Y, Durst GL, Barr RJ, Montrose-Rafizadeh C, Osborne HE, Amos RM, Guo S, Boodhoo A, Krishnan V. Benzopyrans are selective estrogen receptor β agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 2006;49:6155-6157.
110. Richardson TI, Dodge JA, Durst GL, Pfeifer LA, Shah J, Wang Y, Durbin JD, Krishnan V, Norman BH. Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 3: Synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. Bioorg Med Chem Lett 2007;17:4824-4828.
111. Norman BH, Richardson TI, Dodge JA, Pfeifer LA, Durst GL, Wang Y, Durbin JD, Krishnan V, Dinn SR, Liu S, Reilly JE, Ryter KT. Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 4: Functionalization of the benzopyran A-ring. Bioorg Med Chem Lett 2007;17:5082-5085.
112. Richardson TI, Dodge JA, Wang Y, Durbin JD, Krishnan V, Norman BH. Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. Bioorg Med Chem Lett 2007;17:5563-5566.
113. Krishnan V, Kroin JS, Norman BH, Thomas EM. Preparation of substituted tetralins as selective estrogen receptor-β agonists. (Eli Lilly & Co.) WO 2006088716 [Chem Abstr 2006;145:271511].
114. Wilkening RR, Ratcliffe RW, Tynebor EC, Wildonger KJ, Fried AK, Hammond ML, Mosley RT, Fitzgerald PMD, Sharma N, McKeever BM, Nilsson S, Carlquist M, Thorsell A, Locco L, Katz R, Frisch K, Birzin ET, Wilkinson HA, Mitra S, Cai S, Hayes EC, Schaeffer JM, Rohrer SP. The discovery of tetrahydrofluorenones as a new class of estrogen receptor β-subtype selective ligands. Bioorg Med Chem Lett 2006;16:3489-3494.
115. Wildonger KJ, Ratcliffe RW, Mosley RT, Hammond ML, Birzin ET, Rohrer SP. Tetrahydrofluorenones with conformationally restricted side chains as selective estrogen receptor beta ligands. Bioorg Med Chem Lett 2006;16:4462-4466.
116. Scott JP, Ashwood MS, Brands KMJ, Brewer SE, Cowden CJ, Dolling UH, Emerson KM, Gibb AD, Goodyear A, Oliver SF, Stewart GW, Wallace DJ. Development of a phase transfer catalyzed asymmetric synthesis for an estrogen receptor beta selective agonist. Org Process Res Dev 2008;12:723-730.
117. Wilkening RR, Ratcliffe RW, Fried AK, Meng D, Sun W, Colwell L, Lambert S, Greenlee M, Nilsson S, Thorsell A, Mojena M, Tudela C, Frisch K, Chan W, Birzin ET, Rohrer SP, Hammond ML. Estrogen receptor β-subtype selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere. Bioorg Med Chem Lett 2006;16:3896-3901.
118. Kinzel O, Fattori D, Muraglia E, Gallinari P, Nardi MC, Paolini C, Roscilli G, Toniatti C, Gonzalez Paz O, Laufer R, Lahm A, Tramontano A, Cortese R, De Francesco R, Ciliberto G, Koch U. A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies. J Med Chem 2006;49:5404-5407.
119. Parker DL, Jr, Meng D, Ratcliffe RW, Wilkening RR, Sperbeck DM, Greenlee ML, Colwell LF, Lambert S, Birzin ET, Frisch K, Rohrer SP, Nilsson S, Thorsell AG, Hammond ML. Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists. Bioorg Med Chem Lett 2006;16:4652-4656.
120. Mewshaw RE, Edsall RJ, Cohn ST, Harris HA, Keith JC, Jr, Albert LM. Substituted 6H-dibenzo[c, h]chromenes active as estrogenic agents, and their preparation, pharmaceutical compositions, and use. (Wyeth Ltd) WO 2003051863 [Chem Abstr 2003;139:69149].
121. Keith JC, Vlasuk GP. Use of ER-beta selective ligands for treating acute lung injuries. (Wyeth Ltd) US 2008182872 [Chem Abstr 2008;149:239347].
122. Mewshaw RE, Edsall RJ, Jr. Preparation of dibenzo[c, g]chromene derivatives as ERβ selective ligands. (Wyeth Ltd) WO 2005082880 [Chem Abstr 2005;143:286286].
123. Vu AT, Campbell AN, Harris HA, Unwalla RJ, Manas ES, Mewshaw RE. ERβ ligands Part 6: 6H-Chromeno[4, 3-b]quinolines as a new series of estrogen receptor β-selective ligands. Bioorg Med Chem Lett 2007;17:4053-4056.
124. Sun W, Cama LD, Birzin ET, Warrier S, Locco L, Mosley R, Hammond ML, Rohrer SP. 6H-Benzo[c]chromen-6-one derivatives as selective ERβ agonists. Bioorg Med Chem Lett 2006;16:1468-1472.
125. Barrett I, Meegan MJ, Hughes RB, Carr M, Knox AJS, Artemenko N, Golfis G, Zisterer DM, Lloyd DG. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg Med Chem 2008;16:9554-9573.
126. Yang W, Wang Y, Ma Z, Golla R, Stouch T, Seethala R, Johnson S, Zhou R, Güngör T, Feyen JHM, Dickson JK, Jr. Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor β agonists. Bioorg Med Chem Lett 2004;14:2327-2330.
127. Güngör T, Chen Y, Golla R, Ma Z, Corte JR, Northrop JP, Bin B, Dickson JK, Stouch T, Zhou R, Johnson SE, Seethala R, Feyen JHM. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem 2006;49:2440-2455.
128. De Angelis M, Stossi F, Waibel M, Katzenellenbogen BS, Katzenellenbogen JA. Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem 2005;13:6529-6542.
129. Sibley R, Hatoum-Mokdad H, Schoenleber R, Musza L, Stirtan W, Marrero D, Carley W, Xiao H, Dumas J. A novel estrogen receptor ligand template. Bioorg Med Chem Lett 2003;13:1919-1922.
130. Hamann LG, Meyer JH, Ruppar DA, Marschke KB, Lopez FJ, Allegretto EA, Karanewskya DS. Structure-activity relationships and sub-type selectivity in an oxabicyclic estrogen receptor α/β agonist scaffold. Bioorg Med Chem Lett 2005;15:1463-1466.
131. Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem 2006;281:17909-17919.
132. Olsson R, Hyldtoft L, Piu F, Gustafsson M. (ACADIA Pharmaceuticals) Compounds with activity at estrogen receptor. WO2005108337 [Chem Abstr 2005;143:459876].
133. Piu F, Cheevers C, Hyldtoft L, Gardell LR, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Schiffer HH, Donello JE, Olsson R, Gil DW, Brann MR. Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist. Eur J Pharmacol 2008;590:423-429.
134. Gardell LR, Hyldtoft L, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Brann MR, Olsson R, Piu F. Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist. Eur J Pharmacol 2008;592:158-159.
135. Zimmermann J, von Angerer E. Estrogenic and antiestrogenic activities of 2, 4-diphenylfuran-based ligands of estrogen receptors α and β. J Steroid Biochem Mol Biol 2007;104:259-268.
136. Ghosh U, Ganessunker D, Sattigeri VJ, Carlson KE, Mortensen DJ, Katzenellenbogen BS, Katzenellenbogen JA. Estrogenic diazenes: Heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. Bioorg Med Chem 2003;11:629-657.
137. Pirali T, Gatti S, Di Brisco R, Tacchi S, Zaninetti R, Brunelli E, Massarotti A, Sorba G, Canonico PL, Moro L, Genazzani AA, Tron GC, Billington RA. Estrogenic analogues synthesized by click chemistry. Chem Med Chem 2007;2:437-440.
138. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Disc Today 2003;8:1128-1137.
139. Begtrup M, Nielsen CJ, Nygaard L, Samdal S, Sjøgren CE, Sørensen GO. The molecular structure and tautomer equilibrium of gaseous 1, 2, 3-triazole studied by microwave spectroscopy, electron diffraction and Ab initio calculations. Acta Chem Scand 1988;A42:500-514.
140. Pulkkinen JT, Honkakoski P, Peräkyl ä M, Berczi I, Laatikainen R. Synthesis and evaluation of estrogen agonism of diaryl 4, 5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1, 3-diketones: A compound set forming a 4D molecular library. J Med Chem 2008;51:3562-3571.
141. Ohta K, Chiba Y, Ogawa T, Endo Y. Promising core structure for nuclear receptor ligands: Design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton. Bioorg Med Chem Lett 2008;16:5050-5053.
142. Katzenellenbogen JA, Katzenellenbogen BS, Compton DR. Benzenesulfonamides as selective estrogen receptor ligands. US2007021495 [Chem Abstr 2007;146:156287].
143. De Angelis M, Katzenellenbogen JA. Ring nitrogen-substituted non-steroidal estrogens: Pyridine and pyrimidine analogs of the phenol in deoxyhexestrol experience resonance constraints on preferred ligand conformation. Bioorg Med Chem Lett 2004;14:5835-5839.
144. Waibel M, De Angelis M, Stossi F, Kieser KJ, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta. Eur J Med Chem 2009;44:3412-3424.
145. Waibel M, Kieser KJ, Carlson KE, Stossi F, Katzenellenbogen BS, Katzenellenbogen JA. Phenethyl pyridines with non-polar internal substitutents as selective ligands for estrogen receptor beta. Eur J Med Chem 2009;44:3560-3570.
146. Sarachine M, Janjic JM, Wipf P, Day BW. Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor β. Bioorg Med Chem Lett 2009;19:2404-2408.
147. Lin Z, Shen H, Huang J, Chen S, Chen L, Chen J, Liu G, Jiang H, Shen X. Butyl 4-(butyryloxy)benzoate functions as a new selective estrogen receptor β agonist and induces GLUT4 expression in CHO-K1 cells. J Steroid Biochem 2008;110:150-156.
148. Chen W, Lin Z, Ning M, Yang C, Yan X, Xie Y, Shen X, Wang M-W. Aza analogues of equol: Novel ligands for estrogen receptor β. Bioorg Med Chem 2007;15:5828-5836.
149. Kirkiacharian S, Lormier AT, Chidiack H, Bouchoux F, Evelyne Cérède E. Synthesis and binding affinity to human α and β estrogen receptors of various 7-hydroxycoumarins substituted at 4- and 3, 4- positions. Farmaco 2004;59:981-986.
150. Roelens F, Heldring N, Dhooge W, Bengtsson M, Comhaire F, Gustafsson JÅ, Treuter E, De Keukeleire D. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors α and β. J Med Chem 2006;49:7357-7365.
151. De Keukeleire D, Roelens F, Dhooge W. (Universiteit Gent) Preparation of naringenin derivatives with selectivity on estrogen receptors. WO2007053915 [Chem Abstr 2007;146:521587].
152. Compton DR, Carlson KE, Katzenellenbogen JA. Pyrazolo[1, 5-a]pyrimidines as estrogen receptor ligands: Defining the orientation of a novel heterocyclic core. Bioorg Med Chem Lett 2004;14:5681-5684.
153. Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenellenbogen BS, Katzenellenbogen JA. Pyrazolo[1, 5-a]pyrimidines: Estrogen receptor ligands possessing estrogen receptor β antagonist activity. J Med Chem 2004;47:5872-5893.
154. Zhou HB, Sheng S, Compton DR, Kim Y, Joachimiak A, Sharma S, Carlson KE, Katzenellenbogen BS, Nettles KW, Greene GL, Katzenellenbogen JA. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem 2007;50:399-403.
155. Muthyala RS, Sheng S, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Bridged bicyclic cores containing a 1, 1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem 2003;46:1589-1602.
156. Seo JW, Comninos JS, Chi DY, Kim DW, Carlson KE, Katzenellenbogen JA. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: Synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem 2006;49:2496-2511.
157. Kim SH, Katzenellenbogen JA. Hormone-PAMAM dendrimer conjugates: Polymer dynamics and tether structure affect ligand access to receptors. Angew Chem Int Ed 2006;45:7243-7248.
158. Muthyala RS, Carlson KE, Katzenellenbogen JA. Exploration of the bicyclo[3.3.1]nonane system as a template for the development of new ligands for the estrogen receptor. Bioorg Med Chem 2003;13:4485-4488.
159. Zhou H-B, Comninos JS, Stossi F, Katzenellenbogen BS, Katzenellenbogen JA. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure. J Med Chem 2005;48:7261-7274.
160. Zhou HB, Nettles KW, Bruning JB, Kim Y, Joachimiak A, Sharma S, Carlson KE, Stossi F, Katzenellenbogen BS, Greene GL, Katzenellenbogen JA. Elemental isomerism: A boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol 2007;14:659-669.
161. Jeanes HL, Tabor C, Black D, Ederveen A, Gray GA. Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER) α agonist and unaffected by an ERβ antagonist. J Endocrinol 2008;197:493-501.
162. 18F]fluoro-17β-estradiol. J Med Chem 2005;48:6366-6378.
163. Moon BS, Katzenellenbogen JA, Cheon GJ, Chi DY, Lee KC, An GI. Synthesis and evaluation of estrogen receptor β-selective ligands: Fluoroalkylated indazole estrogens. Bull Korean Chem Soc 2008;29:1107-1114.
164. Moon BS, Carlson KE, Katzenellenbogen JA, Choi TH, Chi DY, Kim JY, Cheon GJ, Koh KY, Lee KC, An G. Synthesis and evaluation of aryl-substituted diarylproprionitriles, selective ligands for estrogen receptor β, as positron-emission tomographic imaging agents. Bioorg Med Chem 2009;17:3479-3488.
165. Zhou D, Zhou H, Jenks CC, Lewis JS, Katzenellenbogen JA, Welch MJ. Bromination from the macroscopic level to the tracer radiochemical level: 76Br radiolabeling of aromatic compounds via electrophilic substitution. Bioconj Chem 2009;20:808-816.
166. 99mTc(I) chelates. J Am Chem Soc 2006;128:14476-14477.
167. Nayak TK, Hathaway H J, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER. Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med 2008;49:978-986.
168. Causey PW, Besanger TR, Valliant JF. Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor. J Med Chem 2008;51:2833-2844.
169. Vessières A, Top S, Pigeon P, Hillard E, Boubeker L, Spera D, Jaouen G. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. J Med Chem 2005;48:3937-3940.
170. Hillard E, Vessières A, Le Bideau F, Plazżuk D, Spera D, Huché M, Jaouen G. A series of unconjugated ferrocenyl phenols: Prospects as anticancer agents. ChemMedChem 2006;1:551-559.
171. Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997;62:268-303.
172. Hartman J, Strom A, Gustafsson J-Å. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 2009;74:635-641.
173. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson J-Å. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002;9:1-13.
174. Roger P, Esslimani-Sahla M, Delfour C, Lazennec G, Rochefort H, Maudelonde T. Expression of estrogen receptors alpha and beta in early steps of human breast carcinogenesis. Adv Exp Med Biol 2008;617:139-148.
175. Roger P, Sahla ME, Makela S, Gustafsson J-Å, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61:2537-2541.
176. Speirs V. Oestrogen receptor beta in breast cancer: Good, bad or still too early to tell? J Pathol 2002;197:143-147.
177. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Oestrogen receptor beta: What it means for patients with breast cancer. Lancet Oncol 2004;5:174-181.
178. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003;27:1502-1512.
179. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6:181-202.
180. Cheng G, Weihua Z, Warner M, Gustafsson J-Å. Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci USA 2004;101:3739-3746.
181. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA. Pyrazole ligands: Structure-affinity/activity relationships and estrogen receptor-α selective agonists. J Med Chem 2000;43:4934-4947.
182. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Strom A, Gustafsson J-Å, Rietjens I, Murk AJ. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 2008;105:303-311.
183. Helguero LA, Faulds MH, Gustafsson J-Å, Haldosen LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005;24:6605-6616.
184. Green CA, Peter MB, Speirs V, Shaaban AM. The potential role of ER beta isoforms in the clinical management of breast cancer. Histopathology 2008;53:374-380.
185. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006;95:616-626.
186. Skliris GP, Leygue E, Watson PH, Murphy LC. Estrogen receptor alpha negative breast cancer patients: Estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 2008;109:1-10.
187. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI, Paniagua R. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001;168:447-454.
188. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233-244.
189. Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
190. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003;54:79-87.
191. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004;566:169-172.
192. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004;64:814-820.
193. Bonkhoff H, Motherby H, Fixemer T. New insights into the role of estogens and their receptors in prostate cancer. Urologe A 2003;42:1594-1601.
194. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. ERbeta isoform expression in colorectal carcinoma: An in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005;207:53-60.
195. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001;61:632-640.
196. Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol 2009;305:12-21.
197. Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr Oncol Rep 2004;6:259-267.
198. Ali G, Donati V, Loggini B, Servadio A, Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A, Fontanini G. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008;39:1465-1473.
199. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005;130:979-986.
200. Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM, Nichols M. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116:102-109.
201. Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Muller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci USA 2004;101:5129-5134.
202. Wahlgren A, Svechnikov K, Strand ML, Jahnukainen K, Parvinen M, Gustafsson J-Å, Soder O. Estrogen receptor beta selective ligand 5alpha-Androstane-3beta, 17beta-diol stimulates spermatogonial deoxyribonucleic acid synthesis in rat seminiferous epithelium in vitro. Endocrinology 2008;149:2917-2922.
203. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002;143:4172-4177.
204. Opas EE, Gentile MA, Kimmel DB, Rodan GA, Schmidt A. Estrogenic control of thermoregulation in ERalphaKO and ERbetaKO mice. Maturitas 2006;53:210-216.
205. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
206. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001;103:423-428.
207. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol 2000;278:H1640-H1647.
208. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson J-Å, Mendelsohn ME. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002;295:505-508.
209. Pelzer T, Loza PA, Hu K, Bayer B, Dienesch C, Calvillo L, Couse JF, Korach KS, Neyses L, Ertl G. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation 2005;111:1492-1498.
210. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, Rockman HA, Korach KS, Murphy E. Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 2005;288:H469-H476.
211. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008;180:630-636.
212. Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Lyttle CR. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20:936-941.
213. Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Jr, Harris HA. WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med 2006;34:2188-2193.
214. Yu HP, Hsieh YC, Suzuki T, Shimizu T, Choudhry MA, Schwacha MG, Chaudry IH. Salutary effects of estrogen receptor-beta agonist on lung injury after trauma-hemorrhage. Am J Physiol Lung Cell Mol Physiol 2006;290:L1004-L1009.
215. Miller NR, Jover T, Cohen HW, Zukin RS, Etgen AM. Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death. Endocrinology 2005;146:3070-3079.
216. Carswell HV, Macrae IM, Gallagher L, Harrop E, Horsburgh KJ. Neuroprotection by a selective estrogen receptor beta agonist in a mouse model of global ischemia. Am J Physiol Heart Circ Physiol 2004;287:H1501-H1504.
217. Dubal DB, Rau SW, Shughrue PJ, Zhu H, Yu J, Cashion AB, Suzuki S, Gerhold LM, Bottner MB, Dubal SB, Merchanthaler I, Kindy MS, Wise PM. Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 2006;147:3076-3084.
218. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 2001;98:1952-1957.
219. Simpkins JW, Yang SH, Sarkar SN, Pearce V. Estrogen actions on mitochondria-physiological and pathological implications. Mol Cell Endocrinol 2008;290:51-59.
220. Leventhal L, Brandt MR, Cummons TA, Piesla MJ, Rogers KE, Harris HA. An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain. Eur J Pharmacol 2006;553:146-148.
221. Rocha BA, Fleischer R, Schaeffer JM, Rohrer SP, Hickey GJ. 17 Beta-estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-beta knockout (BERKO) mice. Psychopharmacology (Berl) 2005;179:637-643.
222. Krezel W, Dupont S, Krust A, Chambon P, Chapman PF. Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice. Proc Natl Acad Sci USA 2001;98:12278-12282.
223. Choleris E, Clipperton AE, Phan A, Kavaliers M. Estrogen receptor beta agonists in neurobehavioral investigations. Curr Opin Investig Drugs 2008;9:760-773.
224. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 2004;78:523-529.
225. Lund TD, Rovis T, Chung WC, Handa RJ. Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology 2005;146:797-807.
226. Weiser MJ, Foradori CD, Handa RJ. Estrogen receptor beta in the brain: From form to function. Brain Res Rev 2008;57:309-320.
227. Rissman EF. Roles of oestrogen receptors alpha and beta in behavioural neuroendocrinology: Beyond Yin/Yang. J Neuroendocrinol 2008;20:873-879.
228. Morissette M, Le Saux M, D'Astous M, Jourdain S, Al Sweidi S, Morin N, Estrada-Camarena E, Mendez P, Garcia-Segura LM, Di Paolo T. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol 2008;108:327-338.
229. Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A. The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 2008;73:874-879.
230. Cooke PS, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol 2001;178:147-154.
231. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 2000;97:12729-12734.
232. Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cooke PS. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): A potential role for estrogen receptor beta (ERbeta). Horm Metab Res 2002;34:758-763.
233. Hertrampf T, Seibel J, Laudenbach U, Fritzemeier KH, Diel P. Analysis of the effects of oestrogen receptor alpha (ERalpha)- and ERbeta-selective ligands given in combination to ovariectomized rats. Br J Pharmacol 2008;153:1432-1437.